Momelotinib: an emerging treatment for myelofibrosis patients with anemia
Navtemadlin, an MDM2 inhibitor, demonstrated disease‑modifying activity in relapsed/refractory myelofibrosis patients in a phase‑03 trial.
Evidence level: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.